Video Programs

An expert discusses key data points from the KEYNOTE B61 extended follow up of Lenvatinib plus pembrolizumab in first line setting in non-clear cell renal cell carcinoma.

Dr. Plimack provides a brief overview of the prevalence of non-clear cell renal cell carcinoma and a short description of their subtypes.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, give final thoughts on unmet needs in the non-small cell lung cancer space to inform future treatment strategies.

The panel discusses the future of ctDNA in clinical practice as well as sequencing decisions that may lead to adjuvant therapy in addition to neoadjuvant and/or perioperative therapy.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss their institution’s approaches to treatment decision making for patients with resectable non-small cell lung cancer.

Medical professionals discuss perspectives on CheckMate-77T trial results and potential impacts on clinical practice.

Experts review the NEOTORCH study of 400 patients showing favorable outcomes with a hazard ratio for event-free survival of 0.4.

Tina Cascone, MD, PhD, analyzes results from the AEGEAN trial evaluating perioperative immunotherapy in stage II-IIIB non-small cell lung cancer.

Patrick Forde, MBBCh, discusses CheckMate-816 study results, including the high pathological complete response rates within 6 weeks of immunotherapy reported in the trial's third arm.

Panelists examine multidisciplinary teams and coordination of care for patients with non-small cell lung cancer, including when to involve surgeons, oncologists, and radiation oncologists.

Medical professionals discuss the role of neoadjuvant/perioperative immunotherapy in subgroups of patients with NSCLC with actionable genomic aberrations, including a brief look at the ALINA and ADUARA trials.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss the role of molecular profiling to guide precision treatment decisions in non-small cell lung cancer, including the impact of PD-L1 status on neoadjuvant and perioperative approaches.

Marcia S. Brose, MD, PhD, concludes by listing some future directions she’d like to see within the treatment landscape, as well unmet needs that she hopes will be considered.

An expert briefly discusses the second-line treatment options for patients with DTC that have progressed on first-line therapy.

A medical professional explains how the size of lung metastases affect the treatment of DTC and clinician decision-making.

Marcia S. Brose, MD, PhD, introduces our second patient case, a 57-year-old man with DTC.

Dr Brose elaborates on treating patients with DTC with lenvatinib, including starting dosage and toxicities/adverse events.

A medical professional discusses Study 211 data and HRQoL analyses for patients with DTC on lenvatinib.

An expert explains the impact of patient age when taking lenvatinib for treatment.

Dr Brose reviews frontline treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Marcia S. Brose, MD, PhD, introduces our first patient case, a 70-year-old woman with differentiated thyroid cancer (DTC).

Lowell Hart, MD, FACP, discusses what he’d like to see in the future for the treatment of ER+ breast cancer and includes a note concerning Ki-67 analyses.

Dr Hart explains his prognosis for our case patient.

Lowell Hart, MD, FACP, lists the different types of adverse events that are common when CDK4/6 inhibitors are used in both the adjuvant and advanced cancer setting.

Dr Hart delves into the CDK4/6 inhibitor clinical trials for breast cancer, some that he’s even participated in.

Dr Hart explains the different adjuvant therapy options for patients with HR+ breast cancer.

Lowell Hart, MD, FACP, introduces our patient case, a 54-year-old woman with ER+/PR+ breast cancer, and discusses his strategy and the risk of recurrence for the disease.

Dan Petrylak, MD, discusses the pros and cons of using abiraterone as a front-line therapy for mCSPC and provides details of the PEACE-1 study.